CERE insider transaction filings
Cerevel Therapeutics Holdings, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-08-05. Screen CERE transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for CERE between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Cerevel Therapeutics Holdings, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-08-05 | 4 | Sanchez Ramiro — Chief Medical Officer | Disposition to issuer (D): 14,673 · Disposition to issuer (D): 1,393,153 (derivative) · Disposition to issuer (D): 87,573 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Akamine Scott — Chief Legal Officer | Disposition to issuer (D): 7,527 · Disposition to issuer (D): 367,126 (derivative) · Disposition to issuer (D): 59,171 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Renger John — Chief Scientific Officer | Disposition to issuer (D): 6,370 · Disposition to issuer (D): 778,418 (derivative) · Disposition to issuer (D): 15,061 (derivative) @ $0 · Disposition to issuer (D): 87,573 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Tregoning Kathleen — See Remarks | Disposition to issuer (D): 10,666 · Disposition to issuer (D): 614,428 (derivative) · Disposition to issuer (D): 59,171 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | ALTSCHULLER Susan — Chief Financial Officer | Disposition to issuer (D): 16,913 · Disposition to issuer (D): 124,168 (derivative) · Disposition to issuer (D): 81,065 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Bodenrader Mark — See Remarks | Disposition to issuer (D): 17,724 · Disposition to issuer (D): 277,817 (derivative) · Disposition to issuer (D): 24,852 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | PFIZER INC | Code (U): 27,349,211 @ $45 | EDGAR |
| 2024-08-05 | 4 | Burgess Paul D. — See Remarks | Disposition to issuer (D): 45,727 · Disposition to issuer (D): 95,931 (derivative) · Disposition to issuer (D): 81,065 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Koppel Adam — Director, 10% owner | Disposition to issuer (D): 3,282 · Disposition to issuer (D): 10,461 · Disposition to issuer (D): 65,679,781 · Disposition to issuer (D): 80,189 (derivative) | EDGAR |
| 2024-08-05 | 4 | DiPietro Kenneth — Chief Human Resources Officer | Disposition to issuer (D): 25,042 · Disposition to issuer (D): 711,827 (derivative) · Disposition to issuer (D): 63,905 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Mckernan Ruth — Director | Disposition to issuer (D): 3,282 · Disposition to issuer (D): 10,461 · Disposition to issuer (D): 92,986 (derivative) | EDGAR |
| 2024-08-05 | 4 | Gordon Christopher R — Director, 10% owner | Disposition to issuer (D): 3,282 · Disposition to issuer (D): 10,461 · Disposition to issuer (D): 65,679,781 · Disposition to issuer (D): 80,189 (derivative) | EDGAR |
| 2024-08-05 | 4 | Giordano Douglas E. — Director | Disposition to issuer (D): 3,282 · Disposition to issuer (D): 10,461 · Disposition to issuer (D): 95,242 (derivative) | EDGAR |
| 2024-08-05 | 4 | Renaud Ronald C JR — President & CEO, Director | Disposition to issuer (D): 160,452 · Disposition to issuer (D): 83,857 · Disposition to issuer (D): 215,749 (derivative) · Disposition to issuer (D): 284,023 (derivative) @ $0 · Disposition to issuer (D): 320,742 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Sulzberger Gabrielle — Director | Disposition to issuer (D): 48,415 · Disposition to issuer (D): 10,461 · Disposition to issuer (D): 95,242 (derivative) | EDGAR |
| 2024-08-05 | 4 | DEKKERS MARIJN E — Director | Disposition to issuer (D): 31,822 · Disposition to issuer (D): 10,461 · Disposition to issuer (D): 402,326 · Disposition to issuer (D): 95,242 (derivative) | EDGAR |
| 2024-08-05 | 4 | COLES N ANTHONY — Director | Disposition to issuer (D): 15,638 · Disposition to issuer (D): 10,290 · Disposition to issuer (D): 4,809,418 (derivative) · Disposition to issuer (D): 46,322 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | RIEDEL NORBERT G — Director | Disposition to issuer (D): 46,092 · Disposition to issuer (D): 10,461 · Disposition to issuer (D): 95,242 (derivative) | EDGAR |
| 2024-08-05 | 4 | PATRICK DEVAL L — Director | Disposition to issuer (D): 3,282 · Disposition to issuer (D): 10,461 · Disposition to issuer (D): 49,794 (derivative) | EDGAR |
| 2024-08-05 | 4 | BAIN CAPITAL INVESTORS LLC — Director, 10% owner BC Perception Holdings, LP — Director, 10% owner BCPE Perception GP, LLC — Director, 10% owner Bain Capital Fund XII, LP — Director, 10% owner Bain Capital Partners XII, LLC — Director, 10% owner | Disposition to issuer (D): 65,679,781 | EDGAR |
| 2024-07-03 | 4 | COLES N ANTHONY — Director | Option exercise (M): 25,000 @ $3.50 · Sale (S): 25,000 @ $41.18 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Koppel Adam — Director, 10% owner | Grant/award (A): 10,461 | EDGAR |
| 2024-06-07 | 4 | Mckernan Ruth — Director | Grant/award (A): 10,461 | EDGAR |
| 2024-06-07 | 4 | Gordon Christopher R — Director, 10% owner | Grant/award (A): 10,461 | EDGAR |
| 2024-06-07 | 4 | Giordano Douglas E. — Director | Grant/award (A): 10,461 | EDGAR |
| 2024-06-07 | 4 | Sulzberger Gabrielle — Director | Grant/award (A): 10,461 | EDGAR |
| 2024-06-07 | 4 | DEKKERS MARIJN E — Director | Grant/award (A): 10,461 | EDGAR |
| 2024-06-07 | 4 | COLES N ANTHONY — Director | Grant/award (A): 10,290 | EDGAR |
| 2024-06-07 | 4 | RIEDEL NORBERT G — Director | Grant/award (A): 10,461 | EDGAR |
| 2024-06-07 | 4 | PATRICK DEVAL L — Director | Grant/award (A): 10,461 | EDGAR |
| 2024-06-05 | 4 | COLES N ANTHONY — Director | Option exercise (M): 50,000 @ $3.50 · Sale (S): 50,000 @ $40.61 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | COLES N ANTHONY — Director | Option exercise (M): 50,000 @ $3.50 · Sale (S): 50,000 @ $42.10 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | COLES N ANTHONY — Director | Option exercise (M): 50,000 @ $3.50 · Sale (S): 50,000 @ $42.33 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-06 | 4 | COLES N ANTHONY — Director | Option exercise (M): 50,000 @ $3.50 · Sale (S): 50,000 @ $41.01 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | COLES N ANTHONY — Director | Option exercise (M): 50,000 @ $3.50 · Sale (S): 50,000 @ $41.16 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | PERCEPTIVE ADVISORS LLC — Director PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — Director EDELMAN JOSEPH — Director | Gift (G): 170,317 @ $0 | EDGAR |
| 2024-02-08 | 4 | Renger John — Chief Scientific Officer | Option exercise (M): 5,020 · Sale (S): 2,161 @ $41.54 · Option exercise (M): 5,020 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | COLES N ANTHONY — Director | Option exercise (M): 15,440 · Sale (S): 2,506 @ $41.54 · Option exercise (M): 15,440 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | ALTSCHULLER Susan — Chief Financial Officer | Grant/award (A): 81,065 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Renger John — Chief Scientific Officer | Grant/award (A): 87,573 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Tregoning Kathleen — See Remarks | Grant/award (A): 59,171 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Bodenrader Mark — See Remarks | Grant/award (A): 24,852 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Sanchez Ramiro — Chief Medical Officer | Grant/award (A): 87,573 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Akamine Scott — Chief Legal Officer | Grant/award (A): 59,171 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Burgess Paul D. — See Remarks | Grant/award (A): 81,065 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | DiPietro Kenneth — Chief Human Resources Officer | Grant/award (A): 63,905 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Renaud Ronald C JR — President & CEO, Director | Grant/award (A): 284,023 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | COLES N ANTHONY — Director | Option exercise (M): 50,000 @ $3.50 · Sale (S): 50,000 @ $42.24 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2023-12-28 | 4 | Tregoning Kathleen — See Remarks | Option exercise (M): 3,150 @ $10.05 · Option exercise (M): 3,150 (derivative) @ $0 | EDGAR |
| 2023-12-28 | 4 | Sanchez Ramiro — Chief Medical Officer | Option exercise (M): 10,000 @ $3.50 · Sale (S): 10,000 @ $42.47 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cerevel Therapeutics Holdings, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-08-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CERE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →